CHICAGO--(BUSINESS WIRE)--The investigational antihypertensive drug Cleviprex™ (clevidipine butyrate injectable emulsion) rapidly reduced blood pressure and maintained blood pressure control in patients presenting to the emergency department with acute hypertension, according to data from the Phase III trial VELOCITY* presented today at the annual meeting of the American College of Chest Physicians (CHEST).1
